Skip to NavigationSkip to content

GSK's new President of Global Pharma join date revealed as AZ drops lawsuit

Published on 20/06/17 at 10:10am

The transition of former AstraZeneca Executive Vice President for Europe Luke Miels to rival pharma giant GlaxoSmithKline has not been a smooth one. Miels left AZ in January to join GSK as the firm’s President of Global Pharmaceuticals, only to face a lawsuit from his former employer over allegations he breached the terms of his contract.

When said lawsuit was launched last month, Miels’ still had not joined GSK, nor was a prospective date given for when that may happen. Now, the company has announced that Miels will join on 4 September, following discussions with AZ which sought to neutralise tensions; as a result, Miels will not face a court case over his alleged contract breach.

GSK’s original plan was have Miels work alongside his predecessor Abbas Hussein as part of a handover period, but recent events rendered this unfeasible.

Miels’ role will be an important asset to the company and to GSK CEO Emma Walmsley, who has drawn concern over her lack of scientific background and has worked predominantly in marketing and management. It is believed that she will rely heavily on Miels’ expertise going forward. He joins the company as it stands ready to launch a new set of products from its pipeline.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches